Spectral Diagnostics (OTCMKTS:EDTXF) Stock Price Up 4.7% – Time to Buy?

Spectral Diagnostics Inc. (OTCMKTS:EDTXFGet Free Report) shares traded up 4.7% on Monday . The stock traded as high as $0.9970 and last traded at $0.9970. 1,200 shares changed hands during mid-day trading, a decline of 75% from the average session volume of 4,745 shares. The stock had previously closed at $0.9518.

Spectral Diagnostics Trading Up 4.7%

The stock has a market capitalization of $291.68 million, a PE ratio of -9.06 and a beta of 0.04. The business’s 50 day moving average is $0.98 and its 200 day moving average is $1.01.

About Spectral Diagnostics

(Get Free Report)

Spectral Medical Inc focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies.

Featured Stories

Receive News & Ratings for Spectral Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spectral Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.